[{"address1": "One Cavendish Place", "address2": "4th Floor", "city": "London", "zip": "W1G 0QF", "country": "United Kingdom", "phone": "44 33 3023 7300", "website": "https://www.mereobiopharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 36, "companyOfficers": [{"maxAge": 1, "name": "Dr. Denise  Scots-Knight Ph.D.", "age": 64, "title": "Co-Founder, CEO & Executive Director", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": 883632, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles  Sermon", "age": 54, "title": "Co-Founder, General Counsel & Company Secretary", "yearBorn": 1969, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John P. Richard M.B.A.", "age": 66, "title": "Co-Founder & Chief Business Officer", "yearBorn": 1957, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Fox CPA", "age": 42, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John A. Lewicki Ph.D.", "age": 71, "title": "Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jackie  Parkin", "age": 65, "title": "Senior VP & Therapeutic Head", "yearBorn": 1958, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alexandra  Hughes-Wilson", "age": 52, "title": "Chief of Patient Access & Commercial Planning", "yearBorn": 1971, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Suba  Krishnan", "age": 58, "title": "Senior Vice President of Clinical Development", "yearBorn": 1965, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bo  Kara", "title": "Senior VP and Head of Pharmaceutical Development & CMC", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.92, "open": 3.94, "dayLow": 3.74, "dayHigh": 4.1103, "regularMarketPreviousClose": 3.92, "regularMarketOpen": 3.94, "regularMarketDayLow": 3.74, "regularMarketDayHigh": 4.1103, "beta": 0.802, "forwardPE": -0.07788462, "volume": 2814590, "regularMarketVolume": 2814590, "averageVolume": 1348336, "averageVolume10days": 3461020, "averageDailyVolume10Day": 3461020, "bidSize": 1000, "askSize": 800, "marketCap": 567984192, "fiftyTwoWeekLow": 0.688, "fiftyTwoWeekHigh": 4.18, "priceToSalesTrailing12Months": 79.683525, "fiftyDayAverage": 2.4034, "twoHundredDayAverage": 1.617765, "currency": "USD", "enterpriseValue": 2506904320, "floatShares": 425767499, "sharesOutstanding": 140243008, "sharesShort": 1393547, "sharesShortPriorMonth": 1810035, "sharesShortPreviousMonthDate": 1702598400, "dateShortInterest": 1705017600, "sharesPercentSharesOut": 0.0099, "heldPercentInsiders": 0.00509, "heldPercentInstitutions": 0.52882, "shortRatio": 1.49, "shortPercentOfFloat": 0.0138, "impliedSharesOutstanding": 140243008, "bookValue": 0.46, "priceToBook": 8.804348, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1688083200, "netIncomeToCommon": -26068000, "trailingEps": -0.32, "forwardEps": -52.0, "enterpriseToRevenue": 351.698, "enterpriseToEbitda": -78.604, "52WeekChange": 3.1925135, "SandP52WeekChange": 0.20883334, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "MREO", "underlyingSymbol": "MREO", "shortName": "Mereo BioPharma Group plc", "longName": "Mereo BioPharma Group plc", "firstTradeDateEpochUtc": 1556112600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "2bb59234-2dd4-3418-a5f3-ada28f11788c", "messageBoardId": "finmb_307970474", "gmtOffSetMilliseconds": -18000000, "currentPrice": 4.05, "targetHighPrice": 4.99, "targetLowPrice": 4.0, "targetMeanPrice": 4.25, "targetMedianPrice": 4.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 42113000, "totalCashPerShare": 0.067, "ebitda": -31893000, "totalDebt": 9312000, "quickRatio": 3.027, "currentRatio": 3.106, "totalRevenue": 7128000, "debtToEquity": 16.126, "revenuePerShare": 0.057, "returnOnAssets": -0.20981, "returnOnEquity": -0.40945998, "freeCashflow": -30122500, "operatingCashflow": -33276000, "grossMargins": 0.73750997, "operatingMargins": -1.39015, "financialCurrency": "GBP", "trailingPegRatio": null}]